An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis

American Journal of Medicine

Volumn 116, Issue 11, 2004, Pages 759-766

  Talwalkar, Jayant A ^a   Kamath, Patrick S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFTRIAXONE; NADOLOL; NITRATE; PROPRANOLOL;

ALCOHOL LIVER CIRRHOSIS; ASTHMA; BACTERIAL PERITONITIS; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG UTILIZATION; ESOPHAGUS VARICES; EVIDENCE BASED MEDICINE; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; HYPOTHESIS; INSOMNIA; LABORATORY TEST; LIVER CIRRHOSIS; MORTALITY; PATIENT; PATIENT EDUCATION; PATIENT MONITORING; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCLEROTHERAPY; SEXUAL DYSFUNCTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ESOPHAGEAL AND GASTRIC VARICES; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT SELECTION;

EID: 2442608935     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.03.006     Document Type: Review

References (59)

1. D'Amico G., Pagliaro L., Bosch J. The treatment of portal hypertension a meta-analytic review. Hepatology. 22:1995;332-354
2. D'Amico G., Pagliaro L., Bosch J. Pharmacological treatment of portal hypertension an evidence-based approach. Semin Liver Dis. 19:1999;475-505
3. Grace N. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol. 92:1997;1081-1091
4. Grace N.D., Groszmann R.J., Garcia-Tsao G., et al. Portal hypertension and variceal bleeding an AASLD single topic symposium. Hepatology. 28:1998;868-880
5. Jalan R., Hayes P.C. UK guidelines on the management of variceal hemorrhage in cirrhotic patients. Gut. 46:(suppl 3-4):2000;III1-III15
6. Bosch J., Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 32:(suppl 1):2000;141-156
7. Burroughs A.K., Jenkins W.J., Sherlock S., et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med. 309:1983;1539-1542
8. Lebrec D., Poynard T., Bernuau J., et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis a final report. Hepatology. 4:1984;355-358
9. Villeneuve J.P., Pomier-Layrargues G., Infante-Rivard C., et al. Propranolol for the prevention of recurrent variceal hemorrhage a controlled trial. Hepatology. 6:1986;1239-1243
10. Cerebelaud P., Lavignolle A., Perrin D., et al. Propranolol et prevention des recidives de rupture de varice oesophagienne du cirhotique. Gastroenterol Clin Biol. 18:1986;A10
11. Queuniet A.M., Czernichow P., Lerebours E., et al. Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients. Gastroenterol Clin Biol. 11:1987;41-47
12. Gatta A., Merkel C., Sacerdoti D., et al. Nadolol for prevention of variceal rebleeding in cirrhosis a controlled clinical trial. Digestion. 37:1987;22-28
13. Kobeet E., Schentke K.U. Unsichere rezidivprophylaxe von osophagusvarizenblutungen durch propranolol bei leberzirrhotikern eine prospective kntorllierte sudie. Z Clin Med. 42:1987;507-510
14. Colombo M., de Franchis R., Tommasini M., et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis a multicenter randomized controlled trial. Hepatology. 9:1989;433-438
15. Sheen I.S., Chen T.Y., Liaw Y.F. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver. 9:1989;1-5
16. Garden O.J., Mills P.R., Birnie G.G., et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology. 98:1990;185-190
17. Colman J., Jones P., Finch C., et al. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients. Hepatology. 12:1990;851
18. Rossi V., Cales P., Burtin P., et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients prospective controlled trial of propranolol and sclerotherapy. J Hepatol. 12:1991;283-289
19. McCormick P.A., O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut. 49:2001;682-685
20. Bernard B., Lebrec D., Mathurin P., et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis a meta-analysis. J Hepatol. 26:1997;312-324
21. Bernard B., Lebrec D., Mathurin P., et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis a meta-analysis. Hepatology. 25:1997;63-70
22. Abraczinskas D.R., Ookubo R., Grace N.D., et al. Propranolol for the prevention of first esophageal variceal hemorrhage a lifetime commitment? Hepatology. 34:2001;1096-1102
23. Pascal J.P., Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 317:1987;856-861
24. Ideo G., Bellati G., Fesce E., et al. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics a prospective, randomized study. Hepatology. 8:1988;6-9
25. Strauss E., de Sa M.F.G., Albano A., et al. A randomized controlled trial for the prevention of the first upper gastrointestinal bleeding due to portal hypertension in cirrhosis. Sclerotherapy or propranolol versus control groups. Hepatology. 8:1988;1395
26. Lebrec D., Poynard T., Capron J.P., et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol. 7:1988;118-125
27. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. J Hepatol. 9:1989;75-83
28. Andreani T., Poupon R.E., Balkau B.J., et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology. 12:1990;1413-1419
29. Conn H.O., Grace N.D., Bosch J., et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices a multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology. 13:1991;902-912
30. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients a randomized multicenter trial. Hepatology. 14:1991;1016-1024
31. Van Buuren H.R. The results of two long-term randomized controlled trials evaluating endoscopic sclerotherapy and propranolol as prophylaxis for variceal bleeding. J Hepatol. 23:1995;114
32. Merkel C., Angeli P., Marin R., et al. Beta-blockers in the prevention of aggravation of esophageal varices in patients with cirrhosis and small varices interim analysis of a placebo-controlled clinical trial. Hepatology. 28:1988;453A
33. Poynard T., Cales P., Pasta L., et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 324:1991;1532-1538
34. Merkel C., Marin R., Sacerdoti D., et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 31:2000;324-329
35. Angelico M., Carli L., Piat C., et al. Effects of isosorbide-5- mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology. 113:1997;1632-1639
36. Singh P., Pooran N., Indaram A., et al. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding a meta-analysis. Am J Gastroenterol. 97:2002;623-629
37. Chalasani N., Imperiale T.F. Screening for varices in patients with cirrhosis where do we stand? Am J Gastroenterol. 96:2001;623-624
38. Imperiale T.F., Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 33:2001;802-807
39. Gentilini P., Laffi G., La Villa G., et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 92:1997;66-72
40. Schepis F., Camma C., Niceforo D., et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology. 33:2001;333-338
41. Cales P., Oberti F., Payen J.L., et al. Lack of effect of propranolol in the prevention of large esophageal varices in patients with cirrhosis a randomized trial. Eur J Gastroenterol Hepatol. 11:1999;741-745
42. Jensen D.M. Endoscopic screening for varices in cirrhosis findings, implications, and outcomes. Gastroenterology. 122:2002;1620-1630
43. Pasha T.M., Dickson E.R. Survival algorithms and outcome analysis in primary biliary cirrhosis. Semin Liver Dis. 17:1997;147-158
44. Gores G.J., Wiesner R.H., Dickson E.R., et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis development, natural history, and influence on survival. Gastroenterology. 96:1989;1552-1559
45. Angulo P., Lindor K.D., Therneau T.M., et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 19:1999;115-121
46. Talwalkar J.A., Kamath P.S. Screening for esophageal varices among patients with cirrhosis of the liver. Am J Gastroenterol. 96:2001;3039-3040
47. de Franchis R., Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis. 5:2001;645-663
48. Perez-Ayuso R.M., Pique J.M., Bosch J., et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 337:1991;1431-1434
49. Fucini C., Wolff B.G., Dozois R.R. Bleeding from peristomal varices perspectives on prevention and treatment. Dis Colon Rectum. 34:1991;1073-1078
50. Chen J., Marciniak T.A., Radford M.J., et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol. 34:1999;1388-1394
51. Merican I., Sprengers D., McCormick P.A.e, et al. Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol. 19:1993;15-22
52. Garcia-Pagan J.C., Feu F., Castells A., et al. Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology. 19:1994;595-601
53. Garcia-Pagan J.C., Escorsell A., Moitinho E., et al. Influence of pharmacological agents on portal hemodynamics basis for its use in the treatment of portal hypertension. Semin Liver Dis. 19:1999;427-438
54. Feu F., Garcia-Pagan J.C., Bosch J., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet. 346:1995;1056-1059
55. Escorsell A., Bordas J.M., Castaneda B., et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 31:2000;1061-1067
56. Patch D., Sabin C.A., Goulis J., et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 123:2002;1013-1019
57. Poynard T., Lebrec D., Hillon P., et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis a prospective study of factors associated with rebleeding. Hepatology. 7:1987;447-451
58. Lebrec D., Bernuau J., Rueff B., Benhamou J.P. Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis. N Engl J Med. 307:1982;560
59. Lee S.S., Braillon A., Girod C., et al. Haemodynamic rebound phenomena after abrupt cessation of propranolol therapy in portal hypertensive rats. J Hepatol. 3:1986;38-41